Insider Selling: Corium International Inc (CORI) Director Sells 35,608 Shares of Stock
Corium International Inc (NASDAQ:CORI) Director Robert Thomas sold 35,608 shares of the stock in a transaction that occurred on Wednesday, August 15th. The shares were sold at an average price of $8.86, for a total transaction of $315,486.88. Following the completion of the sale, the director now directly owns 35,608 shares of the company’s stock, valued at approximately $315,486.88. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Shares of NASDAQ:CORI traded up $0.24 during mid-day trading on Friday, reaching $8.93. 241,600 shares of the company were exchanged, compared to its average volume of 265,950. The company has a debt-to-equity ratio of 1.89, a quick ratio of 7.95 and a current ratio of 8.11. The stock has a market capitalization of $313.50 million, a P/E ratio of -5.46 and a beta of 1.45. Corium International Inc has a 1 year low of $7.17 and a 1 year high of $13.93.
Corium International (NASDAQ:CORI) last posted its quarterly earnings data on Thursday, August 9th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.38) by $0.04. The firm had revenue of $7.67 million during the quarter, compared to analysts’ expectations of $6.72 million. Corium International had a negative net margin of 155.21% and a negative return on equity of 298.48%. research analysts forecast that Corium International Inc will post -1.59 earnings per share for the current fiscal year.
Several large investors have recently bought and sold shares of the stock. RTW Investments LP boosted its position in shares of Corium International by 0.7% during the 2nd quarter. RTW Investments LP now owns 1,923,217 shares of the biopharmaceutical company’s stock worth $15,405,000 after purchasing an additional 12,695 shares during the period. BlackRock Inc. boosted its position in shares of Corium International by 17.8% during the 2nd quarter. BlackRock Inc. now owns 2,215,762 shares of the biopharmaceutical company’s stock worth $17,748,000 after purchasing an additional 335,257 shares during the period. Royce & Associates LP boosted its position in shares of Corium International by 99.2% during the 2nd quarter. Royce & Associates LP now owns 502,564 shares of the biopharmaceutical company’s stock worth $4,026,000 after purchasing an additional 250,300 shares during the period. Schwab Charles Investment Management Inc. boosted its position in shares of Corium International by 40.8% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 58,309 shares of the biopharmaceutical company’s stock worth $468,000 after purchasing an additional 16,900 shares during the period. Finally, Engineers Gate Manager LP purchased a new position in shares of Corium International during the 2nd quarter worth approximately $215,000. 95.26% of the stock is owned by hedge funds and other institutional investors.
About Corium International
Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.
Featured Story: Short Selling – Explanation For Shorting Stocks
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.